Alberta Investment Management Corp Has $824,000 Stake in RxSight, Inc. (NASDAQ:RXST)

Alberta Investment Management Corp trimmed its holdings in shares of RxSight, Inc. (NASDAQ:RXST - Free Report) by 51.6% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 23,972 shares of the company's stock after selling 25,602 shares during the period. Alberta Investment Management Corp owned about 0.06% of RxSight worth $824,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in RXST. Brown Capital Management LLC bought a new stake in RxSight during the third quarter worth approximately $26,813,000. Point72 Asset Management L.P. boosted its holdings in RxSight by 610.2% during the third quarter. Point72 Asset Management L.P. now owns 446,976 shares of the company's stock worth $22,094,000 after buying an additional 384,041 shares in the last quarter. Thrivent Financial for Lutherans bought a new stake in RxSight during the third quarter worth approximately $11,350,000. RA Capital Management L.P. boosted its holdings in RxSight by 6.0% during the third quarter. RA Capital Management L.P. now owns 3,916,825 shares of the company's stock worth $193,609,000 after buying an additional 222,000 shares in the last quarter. Finally, Geode Capital Management LLC boosted its holdings in RxSight by 17.7% during the third quarter. Geode Capital Management LLC now owns 817,117 shares of the company's stock worth $40,398,000 after buying an additional 122,775 shares in the last quarter. 78.78% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the stock. Jefferies Financial Group assumed coverage on shares of RxSight in a research report on Tuesday, October 29th. They issued a "buy" rating and a $72.00 price target for the company. Needham & Company LLC restated a "buy" rating and issued a $66.00 price target on shares of RxSight in a research report on Monday, January 13th. Wells Fargo & Company reduced their price target on shares of RxSight from $42.00 to $40.00 and set an "equal weight" rating for the company in a research report on Monday, January 13th. UBS Group assumed coverage on shares of RxSight in a research report on Friday, December 6th. They issued a "buy" rating and a $52.00 price target for the company. Finally, Stifel Nicolaus reduced their price target on shares of RxSight from $40.00 to $35.00 and set a "hold" rating for the company in a research report on Monday, January 13th. Two research analysts have rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to MarketBeat, RxSight presently has a consensus rating of "Moderate Buy" and a consensus price target of $58.13.

RxSight Trading Down 2.4 %

RXST stock traded down $0.73 during midday trading on Friday, reaching $29.60. The company had a trading volume of 526,195 shares, compared to its average volume of 466,024. RxSight, Inc. has a 1 year low of $26.29 and a 1 year high of $66.54. The company has a market capitalization of $1.19 billion, a P/E ratio of -35.66 and a beta of 1.19. The company has a 50 day moving average of $33.14 and a two-hundred day moving average of $43.81.

Insiders Place Their Bets

In other RxSight news, Director Jesse Anderson Corley purchased 1,443 shares of the business's stock in a transaction dated Wednesday, January 15th. The shares were acquired at an average price of $31.18 per share, for a total transaction of $44,992.74. Following the acquisition, the director now owns 1,443 shares of the company's stock, valued at $44,992.74. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Shweta Maniar sold 3,519 shares of the firm's stock in a transaction on Wednesday, January 22nd. The shares were sold at an average price of $30.87, for a total transaction of $108,631.53. Following the transaction, the director now owns 7,383 shares in the company, valued at $227,913.21. This represents a 32.28 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 13,506 shares of company stock worth $567,456 in the last quarter. 9.36% of the stock is currently owned by corporate insiders.

RxSight Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.